Pharmadrug Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pharmadrug Inc. operates as a specialized pharmaceutical enterprise, prioritizing the exploration, enhancement, and market introduction of regulated compounds and natural remedies, encompassing psychedelics and previously approved medications. The company has strategically evolved to focus predominantly on its biotechnology pipeline. Its efforts include developing PD-001, a proprietary oral formulation of cepharanthine designed with enhanced bioavailability, which is being advanced for potential applications in treating viral infectious diseases and rare cancers, including esophageal cancer, for which it holds an orphan drug designation. Clinical manufacturing of PD-001 is underway, with a first-in-human Phase 1 clinical study planned in Australia to evaluate its bioavailability and pharmacokinetics. Further expanding its research initiatives, Pharmadrug is engaged in detailed studies of N,N-dimethyltryptamine (DMT) for non-neuropsychiatric indications, such as ocular diseases including glaucoma, exploring novel formulations and delivery methods. This work is supported by collaborations, notably a research agreement with the University of Michigan to investigate DMT's role in various states of consciousness, and a clinical trial agreement with Johns Hopkins University to assess the acute and lasting psychological and neural impacts of DMT compared to another potent molecule. Through its Super Smart division, the company maintains a presence in the functional mushroom market, having launched premium blends such as Slim MycoWeRx for wellness in the United States. Additionally, Pharmadrug wholly owns SecureDose Synthetics Inc., a pharmaceutical R&D company dedicated to crafting synthetic versions of existing drugs for future market opportunities. In a recent strategic move, the company signed a definitive agreement to acquire an equity interest in Canurta Inc., expanding its focus into cannabinoid-based therapeutics. The company recently completed a debt restructuring and is undertaking a strategic review to enhance shareholder value. Pharmadrug, which was formerly known as Aura Health Inc. until its renaming in October 2019, is headquartered in Toronto, Canada.
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
PharmaDrug Announces Debt Restructuring
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
PharmaDrug Announces Issuance of Debenture Units
PharmaDrug Announces Proposed Issuance of Debenture Units
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Announces Director Appointment and Resignation
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman